GGrantIndex
← Search

transgenic and targeted mutagenesis

$166,629P30FY2009CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

The Northwestern University Transgenic and Targeted Mutagenesis (TTML) is a shared resource designed to produce genetically engineered mice for research projects of investigators of the Robert H Lurie Comprehensive Cancer Center (RHLCCC), Northwestern University's Feinberg School of Medicine (NUFSM), Evanston Northwestern Hospital (ENH) and Children's Memorial Research Center (CMRC). The transgenic laboratory was first organized at the CMRC in 1989 as part of the Markey Program in Developmental Biology, to provide a resource for generating transgenic mice by pronuclear microinjection. In 2003, the laboratory was moved to NUFSM under new leadership by Dr. Warren Tourtellotte and with substantial university support, including newly designed/renovated space and new equipment. Today, the facility has evolved into a highly utilized laboratory that provides a broad range of services to NU investigators, including generation of transgenic mice, gene targeting of embryonic stem (ES) cells, ES cell microinjection into blastocysts, cryopreservation and recovery of mouse embryos, and rederivation of pathogen free mouse strains. Since 2003, the TTML has been highly successful in reorganizing and expanding services, and has been highly successful in generating transgenic and targeted mutant mice. In 2005, services were expanded to offer embryo cryopreservation/recovery, rederivation and in vitro fertilization. The new services position NU and Cancer Center investigators to capitalize on emerging repositories of mutant mice generated around the world, most of which are stored as cryopreserved embryos. The TTML provides the necessary infrastructure to allow most investigators to access transgenic technology that normally requires expensive microinjection/tissue culture equipment and highly skilled staff with expertise in microinjection, microsurgeries, embryo manipulation, animal husbandry, and ES cell culture. TTML staff provide consultation on all aspects of transgenic related technologies ranging from animal protocol approval to breeding, screening and analysis of newly created transgenic or chimeric mice. Moreover, TTML staff are also available to provide guidance regarding targeting vector design, appropriate screening strategies, and DNA isolation methods for gene targeting projects. The TTML is governed by a faculty oversight committee which meets quarterly to provide guidance related to budgetary and operational issues. Over the last five years, Cancer Center investigators have become the primary group of NU investigators utilizing the TTML, emphasizing its pivotal role in the overall research mission of the RHLCCC.

View original record on NIH RePORTER →